Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 Dec;36(12):4022-9.
doi: 10.2337/dc13-0234. Epub 2013 Oct 21.

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Collaborators, Affiliations
Free PMC article
Randomized Controlled Trial

Effects of Naltrexone Sustained-Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes

Priscilla Hollander et al. Diabetes Care. .
Free PMC article

Erratum in

  • Diabetes Care. 2014 Feb;37(2):587

Abstract

Objective: To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs.

Research design and methods: This was a 56-week, double-blind, placebo-controlled study in which 505 patients received standardized lifestyle intervention and were randomized 2:1 to NB or placebo. Coprimary end points were percent weight change and achievement of ≥5% weight loss. Secondary end points included achievement of HbA1c <7% (53 mmol/mol), achievement of weight loss ≥10%, and change in HbA1c, waist circumference, fasting blood glucose, and lipids.

Results: In the modified intent-to-treat population (54% female, 80% Caucasian, and mean age 54 years, weight 106 kg, BMI 37 kg/m(2), and HbA1c 8.0% [64 mmol/mol]), NB resulted in significantly greater weight reduction (-5.0 vs. -1.8%; P < 0.001) and proportion of patients achieving ≥5% weight loss (44.5 vs. 18.9%, P < 0.001) compared with placebo. NB also resulted in significantly greater HbA1c reduction (-0.6 vs. -0.1% [6.6 vs. 1.1 mmol/mol]; P < 0.001), percent of patients achieving HbA1c <7% (53 mmol/mol) (44.1 vs. 26.3%; P < 0.001), and improvement in triglycerides and HDL cholesterol compared with placebo. NB was associated with higher incidence of nausea (42.3 vs. 7.1%), constipation (17.7 vs. 7.1%), and vomiting (18.3 vs. 3.6%). No difference was observed between groups in the incidence of depression, suicidal ideation, or hypoglycemia.

Conclusions: NB therapy in overweight/obese patients with type 2 diabetes induced weight loss, which was associated with improvements in glycemic control and select cardiovascular risk factors and was generally well tolerated with a safety profile similar to that in patients without diabetes.

Figures

Figure 1
Figure 1
A: Body weight change from baseline in the mITT LOCF population. Data are LS mean ± SE. Placebo, n = 159; NB, n = 265. ***P < 0.001 vs. placebo; except for change from baseline to week 56 end point for mITT LOCF population, P values are nominal (i.e., not adjusted for multiple comparisons) and associated with exploratory analyses. B: Body weight change from baseline to week 56 end point; placebo, n = 100; NB, n = 175. ***P < 0.001 vs. placebo; except for ≥5% weight loss category for the mITT-LOCF population, P values are nominal (i.e., not adjusted for multiple comparisons) and associated with exploratory analyses. C: Change in HbA1c from baseline to week 56 end point; placebo, n = 137; NB, n = 222. **P < 0.01 vs. placebo; ***P < 0.001 vs. placebo; the mITT LOCF population consists of patients who had a baseline measurement and at least one postbaseline measurement while on study drug. The last observation on study drug was carried forward. The completer population comprised all randomized patients with a baseline measurement and a 56-week measurement while on the study drug.

Similar articles

See all similar articles

Cited by 66 articles

See all "Cited by" articles

References

    1. Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008;6:343–368 - PubMed
    1. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491–497 - PubMed
    1. Centers for Disease Control and Prevention (CDC) Prevalence of overweight and obesity among adults with diagnosed diabetes—United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 2004;53:1066–1068 - PubMed
    1. Niswender K. Diabetes and obesity: therapeutic targeting and risk reduction - a complex interplay. Diabetes Obes Metab 2010;12:267–287 - PubMed
    1. Hollander PA, Kushner P. Type 2 diabetes comorbidities and treatment challenges: rationale for DPP-4 inhibitors. Postgrad Med 2010;122:71–80 - PubMed

Publication types

MeSH terms

Feedback